JPRN-UMIN000008604已完成2 期
A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic Cancer - Study of Alternate-day dosing for Pancreatic Cancer (PAN-01)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Interstitial pneumonia or pulmonary fibrosis. (2) Watery diarrhea. (3) Severe infections (without viral hepatitis) or being suspected (fever evaluation >=38 degrees). (4) Serious complication (heart failure, renal disorder, liver disorder, bleeding digestive ulcer, intestinal tract paralysis, and etc. ). (5) Moderate or greater pleural effusion, ascites fluid (requiring drainage). (6) Cerebral metastasis. (7) Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration to be within 3 year) except carcinoma in situ or intramucosal cancer. (8) Patients who require administration of flucytosine, phenytoin, and warfarin. (9) Pregnant females or nursing mothers who can not stop lactation after the recruitment. Patients or partners, who don't attempt to doing contraception during the study period. (10) Serious mental disorder. (11) Drug hypersensitivity. (12) Patients who are judged by doctors inappropriate to perform the study safely.
研究者
相似试验
已完成
2 期
Randomized phase II study of dose schedule of TS-1 for resected Colorectal CancerStage III colorectal cancerJPRN-UMIN000013185Clinical Study Group of Osaka (CSGO), Colorectal Cancer Treatment Group170
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-BEEli Lilly & Company Limited488
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDEUCTR2006-002112-99-FREli Lilly & Company Limited488
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDEUCTR2006-002112-99-SEEli Lilly & Company Limited488
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-DEEli Lilly & Company Limited488